This suggests that HLA-DRB1*07 carriers are likely to present tumour cell derived antigenic peptides, and that downregulation of HLA expression in HRS cells is required to overcome CD4+ T cell orchestrated anti-tumour responses. This evidence concerns the gene CD4 and neoplasm.